orlistat and Dyspepsia

orlistat has been researched along with Dyspepsia* in 1 studies

Reviews

1 review(s) available for orlistat and Dyspepsia

ArticleYear
[Dyspeptic syndrome associated with antidiabetic therapy].
    Vnitrni lekarstvi, 2011, Volume: 57, Issue:4

    Dyspeptic syndrome is a common complication of treatment with antidiabetic drugs. This may be a trivial as well as a very serious complication. Nausea, vomiting, diarrhoea, abdominal pain, loss of appetite and taste disturbances are the most common symptoms of dyspeptic problems in patients treated with metformin. They rarely are a reason for treatment discontinuation. Dyspeptic syndrome is a common complication in patients treated with acarbose, this may be prevented by reduced intake of sucrose. Pneumatosis cystoides intestinalis is a rare complication in acarbose-treated patients. Antiobesity agent orlistat is frequently associated with dyspeptic symptoms, particularly if fat intake is not reduced. Treatment with drugs affecting the incretin system (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists) is very rarely complicated by acute pancreatitis. Glucagon-like peptide-1 receptor agonists may cause dyspeptic symptoms (nausea, vomiting, diarrhoea) at the beginning of treatment. These complaints usually cease and the treatment usually does not need to be discontinued.

    Topics: Acarbose; Dyspepsia; Humans; Hypoglycemic Agents; Lactones; Metformin; Orlistat

2011